Scinai Immunotherapeutics
SCNI
14 hedge funds and large institutions have $11.5M invested in Scinai Immunotherapeutics in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
270% more capital invested
Capital invested by funds: $3.12M → $11.5M (+$8.4M)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
75% more funds holding
Funds holding: 8 → 14 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
+$1.13M |
| 2 |
Renaissance Technologies
New York
|
+$525K |
| 3 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
+$147K |
| 4 |
Morgan Stanley
New York
|
+$62.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$30.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
-$462K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.61K |
| 3 |
JP Morgan Chase
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
II
1
Ibex Investors
Denver,
Colorado
| $7.47M | -$462K | -287 | -8% |
|
|
JSMC
2
Jess S. Morgan & Co
Los Angeles,
California
| $1.6M | +$1.13M | +703 | New |
|
|
3
Renaissance Technologies
New York
| $1.22M | +$525K | +326 | +154% |
|
4
HighTower Advisors
Chicago,
Illinois
| $435K | +$4.83K | +3 | +2% |
|
|
VF
5
Virtu Financial
New York
| $260K | +$184K | +114 | New |
|
|
BHB
6
Bank Hapoalim BM
Tel Aviv,
Israel
| $207K | +$147K | +91 | New |
|
|
7
Morgan Stanley
New York
| $94K | +$62.8K | +39 | +1,950% |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $78K | -$1.61K | -1 | -3% |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $57K | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| $43K | +$30.6K | +19 | New |
|
11
Wells Fargo
San Francisco,
California
| $27K | +$4.83K | +3 | +33% |
|
|
PA
12
Perennial Advisors
New York
| $11K | +$8.05K | +5 | New |
|
|
PAG
13
Private Advisor Group
Morristown,
New Jersey
| $5K | +$3.22K | +2 | New |
|
|
RWB
14
RMR Wealth Builders
Montclair,
New Jersey
| $5K | +$3.22K | +2 | New |
|
|
15
JP Morgan Chase
New York
| – | -$1K | -2 | Closed |
|
SCNI Hedge Fund Activity: Q2 2020 in Review
14 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2020, worth a combined $11.5M — up 270% from $3.12M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SCNI positions and 1 closed out — a net gain of 6 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Jess S. Morgan & Co, opening a new position worth an estimated $1.13M. The largest seller was Ibex Investors, cutting an estimated $462K.
- 14 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2020, up from 8 in Q1 2020.
- Funds reported $11.5M of Scinai Immunotherapeutics stock for Q2 2020, up 270% quarter-over-quarter.
- 7 funds opened new Scinai Immunotherapeutics positions in Q2 2020 and 1 closed out, a net change of +6 holders.
- The largest Scinai Immunotherapeutics buyer in Q2 2020 was Jess S. Morgan & Co, an estimated $1.13M added.
- The largest Scinai Immunotherapeutics seller in Q2 2020 was Ibex Investors, an estimated $462K sold.
Based on aggregated 13F filings for Q2 2020.